press release-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

news press release media report

year:

select

press release

26 september 2020

alphamab oncology announced first patient dosed in enreach-lung-01 - a pivotal phase ⅲ clinical trial of pd-l1/ctla-4 bispecific antibody kn046 in combination with chemotherapy for the treatment of non-small cell lung cancer we hope this phase ⅲ trial will establish a new standard of care for the first-line treatment of lung cancer.
03 september 2020

alphamab oncology announced that the u.s. food and drug administration (fda) has granted orphan drug designation to kn046 for the treatment of thymic epithelial tumor this is the second odd awarded to alphamab oncology by fda after the first odd awarded to the subcutaneous pd-l1 antibody kn035 by fda for the treatment of biliary track cancer early this year.
02 september 2020

alphamab oncology initiates phase ii registration clinical trial （kn046-205） for bispecific antibody kn046 with a successful researchers’ conference the project is very important to the company's international strategic positioning.
28 august 2020

alphamab oncology announced 2020 interim results, achieving major progress in pipeline product development 2020 is a landmark year. the company has overcome the impact of the covid-19, achieved major progress.
20 august 2020

latest progress! another ind approval for combination therapy of alphamab’s bispecific antibody kn046 alphamab is focusing on combination therapy of immunotherapy and other medicine to improve the efficacy in liver cancer and other gastrointestinal tumors.
18 august 2020

alphamab oncology (9966.hk) is included in the hang seng composite index alphamab oncology (9966.hk) has been included in the hang seng composite index and will take effect on september 7, 2020 (monday).
18 august 2020

alphamab oncology initiates phase iii clinical trial for bispecific antibody kn046 with a successful researchers’ conference this phase ⅲ clinical trial is for kn046's bla registration in china.
30 july 2020

alphamab oncology and kintor pharmaceutical announce partnership to develop combination therapy of kn046 and gt90001 alphamab oncology is actively deploying kn046's combination therapy development strategy. currently, it has initiated 7 combination clinical trials.
13 july 2020

dr. ting xu, chairman of alphamab oncology, won the sixth “suzhou outstanding talent award” the "suzhou outstanding talent award" is the highest talent award established by the suzhou municipal party and government. it is awarded once every three years to various outstanding talents who have...
06 july 2020

jiangsu alphamab’s new manufacturing facilities’ phase i production lines have received “drug production license” this marks that the further improvement of the company's production capabilities, and further expansion of the scale of development.